BACKGROUND: Timing of initial treatment for acute decompensated heart failure (ADHF) varies across hospitals and its impact on outcomes remains poorly defined. We examined the association between time to first intravenous (IV) heart failure (HF) therapy and patient outcomes. METHODS: Using the ADHERE-EM linked to Medicare claims data, we identified patients ≥65 years old who were hospitalized for ADHF and received IV HF therapy during index admission. Cox proportional hazard model was used to assess the association of time to treatment with a composite of 30-day all-cause mortality or re-admission. Generalized linear mixed models were used to examine the association of time to treatment with in-hospital all-cause mortality, index hospitalization length of stay, and total days alive and out-of-hospital at 30 days. RESULTS: Of 6,971 patients, the median time to first IV HF therapy was 2.3-hours (interquartile range 1.1, 4.4). The cumulative incidence of 30-day all-cause mortality or readmission was 27.4%. After adjusting for covariates, time to treatment was not associated with increased risk of composite 30-day all-cause mortality or re-admission (HR 1.00; 95% CI 1.00-1.00; P = .221). However, every hour delay in treatment was associated with a modest increased risk of in-hospital mortality (adjusted OR 1.01; 95% CI 1.00-1.02; P = .001) and an approximately 1.4-hour increase in index admission length of stay (P < .001). CONCLUSION: Among older patients presenting with ADHF, delay in initiating IV HF therapy was associated with modestly higher risk for in-hospital mortality and longer length of stay, but was not associated with 30-day outcomes.
BACKGROUND: Timing of initial treatment for acute decompensated heart failure (ADHF) varies across hospitals and its impact on outcomes remains poorly defined. We examined the association between time to first intravenous (IV) heart failure (HF) therapy and patient outcomes. METHODS: Using the ADHERE-EM linked to Medicare claims data, we identified patients ≥65 years old who were hospitalized for ADHF and received IV HF therapy during index admission. Cox proportional hazard model was used to assess the association of time to treatment with a composite of 30-day all-cause mortality or re-admission. Generalized linear mixed models were used to examine the association of time to treatment with in-hospital all-cause mortality, index hospitalization length of stay, and total days alive and out-of-hospital at 30 days. RESULTS: Of 6,971 patients, the median time to first IV HF therapy was 2.3-hours (interquartile range 1.1, 4.4). The cumulative incidence of 30-day all-cause mortality or readmission was 27.4%. After adjusting for covariates, time to treatment was not associated with increased risk of composite 30-day all-cause mortality or re-admission (HR 1.00; 95% CI 1.00-1.00; P = .221). However, every hour delay in treatment was associated with a modest increased risk of in-hospital mortality (adjusted OR 1.01; 95% CI 1.00-1.02; P = .001) and an approximately 1.4-hour increase in index admission length of stay (P < .001). CONCLUSION: Among older patients presenting with ADHF, delay in initiating IV HF therapy was associated with modestly higher risk for in-hospital mortality and longer length of stay, but was not associated with 30-day outcomes.
Authors: Cristal L Brown; Bradley G Hammill; Laura G Qualls; Lesley H Curtis; Andrew J Muir Journal: J Pain Symptom Manage Date: 2016-06-03 Impact factor: 3.612
Authors: Òscar Miró; Pia Harjola; Xavier Rossello; Víctor Gil; Javier Jacob; Pere Llorens; Francisco Javier Martín-Sánchez; Pablo Herrero; Gemma Martínez-Nadal; Sira Aguiló; María Luisa López-Grima; Marta Fuentes; José María Álvarez Pérez; Esther Rodríguez-Adrada; María Mir; Josep Tost; Lluís Llauger; Frank Ruschitzka; Veli-Pekka Harjola; Wilfried Mullens; Josep Masip; Ovidiu Chioncel; W Frank Peacock; Christian Müller; Alexandre Mebazaa Journal: Eur Heart J Acute Cardiovasc Care Date: 2021-06-30
Authors: Josep Masip; W Frank Peacok; Mattia Arrigo; Xavier Rossello; Elke Platz; Louise Cullen; Alexandre Mebazaa; Susanna Price; Héctor Bueno; Salvatore Di Somma; Mucio Tavares; Martin R Cowie; Alan Maisel; Christian Mueller; Òsar Miró Journal: Eur Heart J Acute Cardiovasc Care Date: 2022-02-08
Authors: Antonio Francesco Corno; Xue Cai; Caroline B Jones; Giuseppina Mondani; Mark R Boyett; Jonathan Charles Jarvis; George Hart Journal: Front Pediatr Date: 2013-10-28 Impact factor: 3.418